Duration Matters: Anticonvulsant Therapy Linked to Bone Loss in Interim Cross-Sectional Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Long-term anticonvulsant use, especially older generations, can decrease bone mineral density and increase fracture risk. Newer anticonvulsants appear to have a less detrimental effect on bone health.
Area Of Science
- Neurology
- Endocrinology
- Orthopedics
Background
- Anticonvulsants are essential for managing neurological and mental disorders.
- Long-term anticonvulsant therapy is linked to reduced bone mineral density (BMD) and increased fracture risk.
- The impact of anticonvulsants on bone microarchitecture requires further investigation.
Purpose Of The Study
- To evaluate the influence of treatment duration with various anticonvulsant generations on BMD and fracture risk.
- To compare bone health outcomes between patients on anticonvulsants and healthy controls.
Main Methods
- Study included 100 adult epilepsy patients on anticonvulsants (>12 months) and 58 healthy controls.
- Quantitative computed tomography assessed BMD in the lumbar vertebrae (L1, L2) and femoral neck.
- Participants underwent clinical, neuropsychological, and bone densitometry assessments.
Main Results
- BMD reductions were noted in 47% of patients and 50% of controls.
- Age significantly impacted BMD; duration of anticonvulsant therapy had a lesser effect.
- First-generation anticonvulsants were associated with lower BMD (p=0.018); therapy duration over 10 years correlated with fracture risk (p<0.001).
Conclusions
- Long-term use of conventional anticonvulsants negatively affects BMD and increases fracture risk.
- New-generation anticonvulsants did not demonstrate significant adverse effects on BMD.
- Further research is needed to elucidate the precise mechanisms of anticonvulsant effects on bone tissue.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...